Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2V617F and prothrombin G20210A gene mutations in a patient with Budd-Chiari syndrome and essential thrombocythemia.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis - 1 Aug 2010

Musallam Khaled M, Aoun Elie G, Mahfouz Rami A, Khalife Mohamad, Taher Ali T

Abstract excerpt

Myeloproliferative disorders and the inherited thrombophilias have been described as the main causes underlying the Budd-Chiari syndrome. Moreover, the presence of the JAK2V617F was associated with a higher frequency of Budd-Chiari syndrome in patients who have overt or even latent myeloproliferative disorder. We herein describe a 28-year-old woman who was diagnosed with Budd-Chiari syndrome and later developed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Budd-Chiari Syndrome
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Prothrombin

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 19223280
DOI: 10.1177/1076029609332110

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2V617F and prothrombin G20210A gene mutations in a patient with Budd-Chiari syndrome and essential thrombocythemia.PMID 19223280Read ↗

Multiple thrombophilic factors in a patient with Budd-Chiari syndrome.Semantic proximity Read ↗

JAK2V617F mutation as a marker of a latent myeloproliferative disorder in a patient with Budd-Chiari syndrome and factor V Leiden mutation.Semantic proximity Read ↗

Budd-Chiari syndrome in a patient heterozygous for both factor V Leiden and the G20210A mutation on the prothrombin gene.Semantic proximity Read ↗

Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.Semantic proximity Read ↗

The presence of the <i>JAK2</i> V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemiaSemantic proximity Read ↗

[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].Semantic proximity Read ↗

Budd-Chiari syndrome in a patient heterozygous for the G20210A mutation of the prothrombin gene.Semantic proximity Read ↗

JAK2V617F mutation in a 9-year-old girl with polycythemia vera and Budd-Chiari syndrome: a case report.Semantic proximity Read ↗

A case of Budd-Chiari syndrome secondary to multiple thrombogenic conditions: a case report and review of literature.Semantic proximity Read ↗

Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.Semantic proximity Read ↗

JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patients.Semantic proximity Read ↗

Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation statusSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.